Rivaroxaban Once-Daily vs. Dose-Adjusted Vitamin K Antagonist on Biomarkers in Acute Decompensated Heart Failure and Atrial Fibrillation (ROAD HF-AF): Rationale and Design of an Investigator-Initiated…

Overview of attention for article published in Frontiers in Cardiovascular Medicine, January 2022

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age and source (59th percentile)

Mentioned by

twitter: 3 X users

Readers on

mendeley: 8 Mendeley

Summary X

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 3,803 followers.

Rivaroxaban Once-Daily vs. Dose-Adjusted Vitamin K Antagonist on Biomarkers in Acute Decompensated Heart Failure and Atrial Fibrillation (ROAD HF-AF): Rationale and Design of an Investigator-Initiated Multicenter Randomized Prospective Open-Labeled Pilot…

31 Jan 2022

Reply Repost Favourite

RT @FrontCVMedicine: New Research: Rivaroxaban Once-Daily vs. Dose-Adjusted Vitamin K Antagonist on Biomarkers in Acute Decompensated Heart…

13 Jan 2022

Reply Repost Favourite

New Research: Rivaroxaban Once-Daily vs. Dose-Adjusted Vitamin K Antagonist on Biomarkers in Acute Decompensated Heart Failure and Atrial Fibrillation (ROAD HF-AF): Rationale and Design of an Investigator-Initiated Multicenter Randomized… https://t.co/7LEX

13 Jan 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.